Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2008

View Archived Issues

OCT-1547, a novel small-molecule candidate for osteoporosis

Endothelin type-A receptor antagonists reported in Concert Pharmaceuticals patent

Antioxidative activity of ZH-67-2-1 linked to antiarthritic effects

Reduction of MRI lesions and relapses in multiple sclerosis with BHT-3009 treatment

Results support potential benefit of ASF-1096 cream 0.5% in cutaneous lupus

Factor Xa inhibitor DU-176b profiled at Daichii Sankyo

Aclasta approved in Europe for osteoporosis in men with high risk of fractures

Nuvelo and ARCA biopharma to merge

TorreyPines Therapeutics to end discovery operations, focus on development

Quark developing QPI-1007 as neuroprotective agent for eye diseases

Affitech achieves new milestone in Roche collaboration

Phase I program completed for R-4996/MEM-63908

Emergent BioSolutions signs contract with BARDA/NIAID for AV-7909

Rolling NDA submission begins for NPL-2008 in autistic disorder

SUVN-502 for Alzheimer's completes phase I study in Switzerland; cleared to begin phase I in India

Takeda withdraws ramelteon MAA in Europe

Avant Immunotherapeutics to change name to Celldex Therapeutics

Recent patents disclose novel neuropsychiatric agents

Columbia Laboratories reports results from phase II trial of vaginally administered lidocaine

First patient treated in phase II IMC-1121B trial in advanced ovarian cancer

Recent Kowa patent describes novel STAT-6 activation inhibitors

Forest, Gedeon Richter report positive phase II results for cariprazine in patients with acute mania

Indevus initiates phase III octreotide implant trial in patients with acromegaly

Potentia presents positive safety data in phase I POT-4 trial

Uluru files 510k submission with FDA for Altrazeal Silver

Aeolus initiates multiple-dose study of AEOL-10150 in ALS

Medivir submits NDA to FDA for Lipsovir

PARP inhibitors identified as protective agents in ischemic-induced brain damage

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026